Combined 5-fluorouracil, low-molecular-weight heparin, and silicone oil in the management of complicated retinal detachment with proliferative vitreoretinopathy grade C

Ophthalmic Surgery Lasers and Imaging

Volumn 38, Issue 4, 2007, Pages 276-282

  Garcia, Reinaldo A ^a   Sanchez, Juan G ^a   Arevalo, J Fernando ^a  

^a Clinica Oftalmologica Centro Caracas   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; LOW MOLECULAR WEIGHT HEPARIN; SILICONE OIL; ANTIMETABOLITE; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; CHI SQUARE TEST; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INFUSION; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RETINA DETACHMENT; TREATMENT DURATION; VITRECTOMY; VITREORETINOPATHY; DRUG COMBINATION; METHODOLOGY; MIDDLE AGED; RECURRENT DISEASE; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; AGED; ANTIMETABOLITES; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; FLUOROURACIL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RETINAL DETACHMENT; SILICONE OILS; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY; VITREORETINOPATHY, PROLIFERATIVE;

EID: 34547680287     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20070701-02     Document Type: Article

References (13)

1. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol. 2004;137:1105-1115.
2. Fekrat S, de Juan E Jr, Campochiaro PA. The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology. 1995;102:412-418.
3. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. 1980;89:131-136.
4. Lemor M, Yeo JH, Glaser BM. Oral colchicine for the treatment of experimental traction retinal detachment. Arch Ophthalmol. 1986;104:1226-1229.
5. Daniels SA, Coonley KG, Yoshizumi MO. Taxol treatment of experimental proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1990;228:513-516.
6. Wiedemann P, Hilgers RD, Bauer P, Heimann K. Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol. 1998;126:550-559.
7. Asaria RH, Kon CH, Bunce C, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: resulrs from a randomized, double-blind, controlled clinical trial. Ophthalmology. 2001;108:1179-1183.
8. Charteris DG, Aylward GW, Wong D, et al. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. 2004;111:2240-2245.
9. Machemer R, Aaberg TM, Freeman HM, Irvine AR, Lean JS, Michels RM. An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol. 1991;112:159-165.
10. Asaria RH. Adjuvant 5-FU and heparin prevent PVR (author's reply). Ophthalmology. 2002;109:830.
11. Alvira G, Hartzer M, Blumenkranz M, Camacho H. Heparin: a possible new approach to the treatment of proliferative vitreoretinopathy. In: Heimann K, Weidemann P, eds. Proliferative Vitreoretinopathy. Heidelberg: Kaden-Verlag; 1989:268-271.
12. Hartzer MK, Blumenkranz MS. Fluoropyrimidines in the treatment of proliferative vitreoretinopathy and glaucoma. In: Tso MOM, ed. Retinal Diseases: Biomedical Foundations and Clinical Management. Philadelphia: Lippincott; 1988.
13. Silicone Study Group. Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol. 1992;110:780-792.